Critical Milestones Achieved Ahead Of Schedule In Lung Cancer Study

IQVIA™ Biotech was selected by a biotechnology company preparing to launch an international Phase III clinical trial for its investigational anaplastic lymphoma kinase (ALK) inhibitor in patients with non-small cell lung cancer (NSCLC). As this was a highly competitive space with more than five companies pursuing the same market, the sponsor’s clinical operations team was seeking an oncology-focused partner who could support protocol design and accelerate the start-up process to meet enrollment milestones quickly. IQVIA Biotech’s oncology team leveraged our extensive NSCLC operational experience, global footprint, and strategic resources to execute this large Phase III study.

Following a competitive review, the sponsor selected IQVIA Biotech to lead the study, managing Europe and Asia, while the sponsor managed North America (NA) in-house. This case study will focus on the ex-NA portion of the clinical trial covering more than 100 sites across nearly 20 countries.